TrademarkDir
CT CELLENGENE CELL AND GENE THERAPY
DEAD

Serial Number

79330615

Owner

Cellengene Inc

Attorney

Louise Arnott

Filing Date

Nov 19, 2021

Add to watchlist:

No watchlists yet
+ Create New Watchlist
View on USPTO

CT CELLENGENE CELL AND GENE THERAPY Trademark

Serial Number: 79330615

CT CELLENGENE CELL AND GENE THERAPY is a trademark filed by Cellengene Inc on November 19, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

Cellengene Inc

16, Daewangpangyo-ro 712 beon-gil,

Entity Type: 03

Trademark Details

Filing Date

November 19, 2021

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations for treating diabetes; pharmaceutical preparations for immunity adjustment; pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for the treatment of cells; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; biopharmaceuticals for the treatment of cancer; biological preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer; biological preparations for medical purposes, namely, biological preparations for the treatment of cancer; stem cells for medical purposes; antidiabetic preparations; anti-diabetic pharmaceuticals; anti-cancer preparations

Medical services in the field of diabetes; medical services relating to the removal, treatment and processing of human blood, umbilical cord blood, human cells, stem cells and bone marrow; health care services for treating cancer; medical services relating to the removal, treatment and processing of human cells; medical analysis relating to clinical data, namely, medical analysis services for diagnostic and treatment purposes provided by medical laboratories

Development of cell therapy products, namely, research and development and consultation related thereto in the field of cell engineering technology; scientific research for medical purposes in the area of cancerous diseases; research services relating to pharmaceuticals, namely, stem cell research services; stem cell research services

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
May 24, 2025 FINT
FINAL DISPOSITION NOTICE SENT TO IB
May 2, 2025 FICS
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
May 2, 2025 FICR
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
May 2, 2024 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
May 2, 2024 ABN2
NOTIFICATION OF FINAL REFUSAL EMAILED
Oct 20, 2023 GNFN
FINAL REFUSAL E-MAILED
Oct 20, 2023 GNFR
FINAL REFUSAL WRITTEN
Oct 20, 2023 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 26, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 26, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 26, 2023 TROA
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jun 26, 2023 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 7, 2023 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jun 7, 2023 OPNR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 30, 2023 GNRN
NON-FINAL ACTION E-MAILED
Jan 30, 2023 GNRT
NON-FINAL ACTION WRITTEN
Jan 30, 2023 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 22, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 22, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 22, 2022 TROA
LETTER OF PROTEST EVIDENCE FORWARDED
Dec 1, 2022 LOPT
REFUSAL PROCESSED BY IB
Nov 27, 2022 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Nov 7, 2022 RFCS
REFUSAL PROCESSED BY MPU
Nov 7, 2022 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 14, 2022 RFCR
NON-FINAL ACTION WRITTEN
Sep 13, 2022 CNRT
ASSIGNED TO EXAMINER
Aug 31, 2022 DOCK
APPLICATION FILING RECEIPT MAILED
Jan 11, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 7, 2022 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jan 6, 2022 REPR

Related Trademarks